| Foreword: Genetic Therapy in the 21st Century |
|
iii | (2) |
|
|
|
|
|
| Preface: From Theory to Practice in Thirty Years |
|
v | (8) |
|
|
|
|
|
| Contributors |
|
xiii | |
|
1. A Brief History of Genetic Therapy: Gene Therapy, Antisense Technology, and Genomics |
|
|
1 | (38) |
|
|
|
|
|
|
2. Preclinical Development of Antisense Oligonucleotide Therapeutics for Cancer: Regulatory Aspects |
|
|
39 | (14) |
|
|
|
|
|
|
|
|
|
|
|
3. Commercial Scale Manufacturing of Oligonucleotides Under Good Manufacturing Practices |
|
|
53 | (36) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4. The Regulatory Process and Gene Therapy |
|
|
89 | (12) |
|
|
|
|
|
|
5. Production of Clinical Lots of Gene Therapy Vectors Using Good Manufacturing Practice: Experience in a University Setting |
|
|
101 | (10) |
|
|
|
|
|
|
|
|
|
|
|
6. Gene Therapy Clinical Trials for Adenosine Deaminase Deficiency/Severe Combined Immunodeficiency |
|
|
111 | (22) |
|
|
|
|
|
|
|
|
|
|
|
7. Development of an Oligodeoxynucleotide Pharmaceutical for the Treatment of Human Leukemia |
|
|
133 | (22) |
|
|
|
|
|
|
|
|
|
|
|
8. Clinical Trials with Anti-p53 DNA, OL(1)p53, in Patients with Acute Myelogenous Leukemia and Myelodysplastic Syndrome |
|
|
155 | (14) |
|
|
|
|
|
|
9. Human Bcl-2 Antisense Therapy for Lymphomas |
|
|
169 | (22) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
10. Retroviral Gene Transfer in Autologous Bone Marrow and Stem Cell Transplantation |
|
|
191 | (28) |
|
|
|
|
|
|
|
|
|
|
|
11. Adenoviral Gene Transfer of the Herpes Virus Thymidine Kinase Gene for Treating Gliomas |
|
|
219 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12. Distribution and Toxicity of Retroviral Vectors After Intracavitary Delivery in Mouse and Man |
|
|
239 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
13. Clinical and Immunologic Responses to Gene Transfer of an Allogeneic Major Histocompatibility Complex Antigen |
|
|
257 | (22) |
|
|
|
|
|
|
|
|
|
|
|
14. Defective Tumor Suppressor Gene Replacement and Oncogene Inactivation for the Treatment of Cancer |
|
|
279 | (16) |
|
|
|
|
|
|
15. The Molecular Basis of Bladder Cancer and Prospects for Gene Therapy Using Hammerhead Ribozymes |
|
|
295 | (16) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16. In Situ Gene Insertion for Immunotherapy Using Vaccinia Virus Vectors |
|
|
311 | (20) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
17. Antisense Oligonucleotide-Based Therapy for HIV-1 Infection from Laboratory to Clinical Trials |
|
|
331 | (22) |
|
|
|
|
|
|
18. Treatment of Retinitis Induced by Cytomegalovirus Using Intravitreal Fomivirsen (Isis 2922) |
|
|
353 | (10) |
|
|
|
|
|
|
19. Synthetic DNA-Based Compounds for the Prevention of Coronary Restenosis: Current Status and Future Challenges |
|
|
363 | (32) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
20. Prevention of Restenosis by Gene Targeting |
|
|
395 | (18) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Index |
|
413 | |
Shopping Cart
